Polidocanol foam sclerotherapy

PreclinicalSmall molecule

Polidocanol foam sclerotherapy is one of 33 small molecule programs targeting Varicose veins. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Varicose VeinsActive, not recruiting

HemorrhoidActive, not recruiting

Varicose VeinsPreclinical

Active, not recruiting

HemorrhoidPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Hemorrhoid

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

1 2

Cardizem

BBausch Health Americas, Inc.

Approved

1 3

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

—4

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Celestone

Kenalog

Flagyl

1 8

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 9

SKY0402

Pacira Pharmaceuticals, Inc

Phase 3

3 10

Botox

RRevance Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Varicose Veins

NCT07276243

Clinical

Trials by Indication[1]

Varicose veins1 trial

Polidocanol Foam With or Without Transdermal Laser for Varicose Veins: Randomized Clinical Trial

Not yet recruiting·HHospital Universitario Pedro Ernesto·N/A·NCT07276243·102 enrolled

Hemorrhoid1 trial

Polidocanol Foam VS Artery Ligation in Hemorrhoidal Disease

Completed·UUniversidade do Porto·Phase 2/3·NCT04675177·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Polidocanol foam sclerotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Polidocanol foam sclerotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Polidocanol foam sclerotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Universitario Pedro Ernesto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHospital Universitario Pedro Ernesto

Polidocanol foam sclerotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Varicose veins1 trial

Hemorrhoid1 trial

References

Drug Info

Quick Facts

Related News